Statement of Changes in Beneficial Ownership (4)
May 25 2022 - 4:04PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Maryles Joel Michael |
2. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd.
[
CMMB
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
5 ATZMON ST. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/24/2022 |
(Street)
HASHMONAIM, L3 7312700
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
American Depositary Shares (1) | 5/24/2022 | | P | | 400 | A | $2.89 | 1400 (2) | D | |
American Depositary Shares (1) | 5/24/2022 | | P | | 33 | A | $2.76 | 1433 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Option to Purchase American Depositary Shares (3) | $3.53 | 3/7/2022 | | A | | 6820 | | (4) | 3/7/2032 | American Depositary Shares (1) | 6820 | $0 | 6820 | D | |
Option to Purchase American Depositary Shares (3) | $27.26 | 4/19/2021 | | A | | 11884 | | (5) | 4/19/2031 | American Depositary Shares (1) | 11884 | $0 | 11884 | D | |
Explanation of Responses: |
(1) | Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
(2) | Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022. |
(3) | No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. |
(4) | These options vest and become exercisable in their entirety on March 16, 2023. |
(5) | These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Maryles Joel Michael 5 ATZMON ST. HASHMONAIM, L3 7312700 | X |
|
|
|
Signatures
|
/s/ David S. Glatt, Esq., Attorney-in-Fact for Joel Michael Maryles | | 5/25/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Jul 2023 to Jul 2024